Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Prostatic Neoplasms 32Lymphoma, Large B-Cell, Diffuse 29Lymphoma, Follicular 15Leukemia 15Lymphoma, Non-Hodgkin 13Hodgkin Disease 11Burkitt Lymphoma 10Leukemia, Biphenotypic, Acute 8Neoplasm Metastasis 7Recurrence 6Neoplasms 6Lymphoma, Large-Cell, Anaplastic 6Lymphoma, B-Cell 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Hemangioma 5Ovarian Neoplasms 4Multiple Myeloma 4Immunoblastic Lymphadenopathy 4Dendritic Cell Sarcoma, Interdigitating 4Metastatic Castration-resistant Prostate Cancer 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell, Marginal Zone 3Breast Neoplasms 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neurotoxicity Syndromes 2

Interventions

Cyclophosphamide 14Dexamethasone 13Vincristine 11Cytarabine 11Methotrexate 9venetoclax 7Inotuzumab Ozogamicin 7Doxorubicin 7pegaspargase 6merphos 6blinatumomab 6Prednisone 6dexamethasone acetate 5dexamethasone 21-phosphate 5Mercaptopurine 5Calcium Dobesilate 5prednylidene 4deltacortene 4azathiopurine 4auricularum 4Specimen Handling 4Leucovorin 4Asparaginase 4Thioguanine 3Rituximab 3N,N-dicyclohexyl-isoborneol-10-sulfonamide 3Methylprednisolone 3fludarabine 2calaspargase pegol 2asparaginase erwinia chrysanthemi recombinant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Prednisolone × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡